HMOX1 pathway signature predicts clinical benefit from immunotherapy plus tyrosine kinase inhibitor therapy in advanced renal cell carcinoma.

Xianglai Xu,Sihong Zhang,Ying Wang,Yanjun Zhu,Jiajun Wang,Jianming Guo

Cancer medicine（2023）

引用 1|浏览27

暂无评分

摘要

Our study identified the HMOX1 pathway signature was a potential prognostic factor of progression-free survival for TKI + IO combination therapy in the advanced RCC in different cohort, especially in first-line management of mRCC in the Javelin 101 cohort. Moreover, HMOX1 signature was associated with T-cell function in tumor environment.

查看译文

关键词

T-cell dysfunction,heme oxygenase 1,immune checkpoint inhibitor,renal cell carcinoma,tyrosine kinase inhibitor

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要